Teva Promises New Strategy By The Summer, Washes Hands Of $1bn US Target
Strategic Review Will Consider ‘How Business Segments Evolve Over Time’
Still only six weeks into the job, Teva’s new CEO Richard Francis and his senior team are busy working on a refreshed company strategy, as Teva looks to grow its top line in 2023 for the first time in six years.
You may also be interested in...
Teva has celebrated a US nod for its generic version of Forteo, the first substitutable teriparatide rival to be approved by the US Food and Drug Administration.
With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.
Teva is just about to unveil a fresh strategy under new CEO Richard Francis, who has emphasized the firm’s “emerging innovative business” and talked up the company’s branded assets ahead of an investor day on 18 May where full details will be revealed.